COMMITTED TO DEVELOPING TARGETED TREATMENTS FOR
DIFFICULT TO TREAT ADVANCED CANCERS

ALONBIO LTD 

AlonBio is an oncology biotechnology company focused on discovering and developing targeted cancer therapies. We identify and target key drivers of cancer cell growth, resistance, and survival.
Our core competencies in cancer biology research and drug development, taken together with our small molecule screening platforms enable a rapid translation of our discoveries into potential treatments for difficult-to-treat aggressive cancers.


Our lead asset BKT300 is a novel, first-in-class, highly selective, PRC1 inhibitor developed as a targeted anti-cancer treatment.

White Background

ESTABLISHED LEADERSHIP

We have assembled an experienced management team with deep expertise in oncology research and drug development. and a demonstrated track record of success building biotech companies and developing novel therapeutics.

 

BOARD OF DIRECTORS

H. Laurence Shaw, M.D.

Chairman

Prof. Amnon Peled, Ph.D.

Chief Scientific Officer

Shmuel Cabilly, Ph.D.

Director

Arnon Aharon, M.D.

Chief Executive Officer

Anthony Trevor Stanton

Director

 
AlonBioVisual.png